Revolutionizing MRI
Contrast Agents for Disease
Detection and Tracking
What if you could detect cancer and other diseases earlier, faster and more easily?
You can with InLighta BioSciences’ patented MRI contrast agents
With InLighta BioSciences, the hope of easier and earlier detection is a reality.
InLighta BioSciences offers precision Magnetic Resonance Imaging (pMRI) technology that addresses current deficiencies in other medical diagnostics making it possible for true early disease detection, faster monitoring disease progression, clearer opportunities to utilize image-guided intervention, and dramatically more effective evaluating drug delivery and therapeutic treatment.
Our Products/ Services
InLighta is currently developing high-contrast agents for MR imaging. The ProCA® series of contrast agents includes both blood pool agents and targeted contrast agents for specific biomarkers.
01
ProCa® Series
(Protein-based Contrast Agents)

02
Blood Pool Agents

03
Targeted Contrast Agents

Latest News
Stay updated with the latest news and developments from InLighta BioSciences.

Explore More
InLighta BioSciences IN THE NEWS
Our Sponsors / Investors
Our Valuable Resources
Conflict of interest policy
Get in Touch
"*" indicates required fields
Contact Information
Atlanta, GA 30303